BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 28257810)

  • 1. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
    Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
    Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
    Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
    Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
    Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
    Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3).
    Rodallec A; Sicard G; Giacometti S; Carre M; Maia T; Valette M; Bouquet F; Savina A; Lacarelle B; Ciccolini J; Fanciullino R
    Anticancer Drugs; 2020 Jun; 31(5):463-472. PubMed ID: 31895102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-conjugated pH-sensitive liposomes for HER-2 positive breast cancer: development, characterization,
    Raikwar S; Yadav V; Jain S; Jain SK
    J Liposome Res; 2024 Jun; 34(2):239-263. PubMed ID: 37594466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.
    Eloy JO; Petrilli R; Topan JF; Antonio HMR; Barcellos JPA; Chesca DL; Serafini LN; Tiezzi DG; Lee RJ; Marchetti JM
    Colloids Surf B Biointerfaces; 2016 May; 141():74-82. PubMed ID: 26836480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound-triggered herceptin liposomes for breast cancer therapy.
    Elamir A; Ajith S; Sawaftah NA; Abuwatfa W; Mukhopadhyay D; Paul V; Al-Sayah MH; Awad N; Husseini GA
    Sci Rep; 2021 Apr; 11(1):7545. PubMed ID: 33824356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.
    Yang T; Choi MK; Cui FD; Lee SJ; Chung SJ; Shim CK; Kim DD
    Pharm Res; 2007 Dec; 24(12):2402-11. PubMed ID: 17828616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted co-delivery of polypyrrole and rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy.
    Nguyen HT; Tran TH; Thapa RK; Phung CD; Shin BS; Jeong JH; Choi HG; Yong CS; Kim JO
    Int J Pharm; 2017 Jul; 527(1-2):61-71. PubMed ID: 28528212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.
    Rodallec A; Brunel JM; Giacometti S; Maccario H; Correard F; Mas E; Orneto C; Savina A; Bouquet F; Lacarelle B; Ciccolini J; Fanciullino R
    Int J Nanomedicine; 2018; 13():3451-3465. PubMed ID: 29950829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.
    Vaidya T; Straubinger RM; Ait-Oudhia S
    Pharm Res; 2018 Mar; 35(5):95. PubMed ID: 29536232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermo- and pH-responsive targeted lipid-coated mesoporous nano silica platform for dual delivery of paclitaxel and gemcitabine to overcome HER2-positive breast cancer.
    Nasri N; Saharkhiz S; Dini G; Yousefnia S
    Int J Pharm; 2023 Dec; 648():123606. PubMed ID: 37972671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO.
    Kullberg M; Mann K; Anchordoquy TJ
    Mol Pharm; 2012 Jul; 9(7):2000-8. PubMed ID: 22621404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.
    Rodallec A; Sicard G; Giacometti S; Carré M; Pourroy B; Bouquet F; Savina A; Lacarelle B; Ciccolini J; Fanciullino R
    Int J Nanomedicine; 2018; 13():6677-6688. PubMed ID: 30425482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome.
    Yang T; Choi MK; Cui FD; Kim JS; Chung SJ; Shim CK; Kim DD
    J Control Release; 2007 Jul; 120(3):169-77. PubMed ID: 17586082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts.
    Yamamoto Y; Yoshida M; Sato M; Sato K; Kikuchi S; Sugishita H; Kuwabara J; Matsuno Y; Kojima Y; Morimoto M; Horiuchi A; Watanabe Y
    Int J Oncol; 2011 Jan; 38(1):33-9. PubMed ID: 21109923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation.
    Ravar F; Saadat E; Gholami M; Dehghankelishadi P; Mahdavi M; Azami S; Dorkoosh FA
    J Control Release; 2016 May; 229():10-22. PubMed ID: 26968799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.